Lupin partners with MonoSol Rx to develop film-based drugs for kids

Films have emerged as an advanced alternative for patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms


Lupin has been building specialty branded portfolio of drugs targeting pediatrics in the US market and created a dedicated national sales force to call upon pediatricians. Photo: Bloomberg
Lupin has been building specialty branded portfolio of drugs targeting pediatrics in the US market and created a dedicated national sales force to call upon pediatricians. Photo: Bloomberg

Hyderabad: India’s third largest drug maker, Lupin Ltd, on Thursday said its US-subsidiary Lupin Pharmaceutical Inc., has entered into a strategic licencing agreement with MonoSol Rx, a specialty pharmaceutical company to develop multiple pediatric products utilizing the later’s proprietary PharmFilm drug delivery technology.

MonoSol Rx’s PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film, Lupin said in a statement.

US-based MonoSol Rx is a global leader in film-based drug delivery applications with two FDA-approved products and a robust pipeline of pharmaceuticals in development, the statement added.

Films have emerged as an advanced alternative for patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms, films provides a minimally invasive alternative to pills, injections, and gels, with the goal of helping patients adhere to their prescribed treatment regimens in order to improve their health.

Similar in size, shape and thickness to a postage stamp, thin-film strips are typically designed for oral administration, with the user placing the strip on or under the tongue.

“The technology could offer potential to support pediatric patients in particular, many of whom have difficulty with the currently available oral or injectable dosing of needed medications,” Lupin said.

The agreement would be in line with the company’s focus on expanding into the specialty pharmaceutical market, and specifically, pediatric needs such as attention-deficit, hyperactivity disorder (ADHD).

Lupin has been building specialty branded portfolio of drugs targeting pediatrics in the US market and created a dedicated national sales force to call upon pediatricians.

The company markets pediatric version of anti-infective product cefixime under brand name Suprax and plans to expand its portfolio.

Lupin and other Indian generic makers in a bid to differentiate from competition are increasingly investing on new drug delivery mechanisms such as films, patches, inhalers and auto-injections in US and elsewhere.

Shares of Lupin Ltd dropped 0.44% to close at Rs1,484.65 on BSE, the benchmark Sensex declined 0.41% to end 28,106.21 points.

More From Livemint